UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

描述（由申请人提供）：位于查佩尔山的北卡罗来纳州大学（北卡罗来纳州）与杜克大学和Hamner药物安全科学研究所合作，为临床药理学的T32培训项目做好了准备。我们在临床药理学方面拥有出色的研究环境，在药物基因组学，药物发现，药物开发和药物安全性方面拥有世界一流的项目，在临床药理学方面培训临床医生-科学家的出色记录，以及优秀的申请人库。本申请中详细介绍的临床药理学培训计划提供了强大的领导力，来自多个学科的国际公认的导师，他们积极参与临床药理学，广泛的尖端技术和资源，以及具有强大机构支持的独特协作环境。该计划的国家申请人库将主要来自寻求临床药理学职业道路的医学专业培训计划的医学博士。学员在个性化辅导团队的指导下，将完成临床药理学课程，并参与特定项目的活动，以获得当代临床药理学研究各个方面的专业知识，从伦理学和药物基因组学到临床试验设计。教师导师的选择是基于他们在临床药理学研究中的生产力，至少有四个重点领域之一，形成了这个培训计划的核心：药物处置和行动;药物基因组学;药物诱导的器官毒性;定量药理学和临床试验设计。该培训计划的一个独特之处是有机会专注于临床药理学的未充分研究领域，特别是儿科和药物安全性。我们潜在的实习生群体对临床药理学的浓厚兴趣，杜克大学和Hamner-Schmidt药物安全科学研究所对临床药理学研究资源的无与伦比的投资，以三角研究园为代表的智力丰富的区域环境，其集中了与临床药理学相关的生物医学科学，以及我们长期以来优秀的研究和培训基础设施联合收割机，为临床药理学培训创造了无与伦比的机会。 公共卫生相关性：对疾病的生物学基础和个体间对药物治疗反应的差异的理解有了很大的发展。这为药物开发和治疗并最终治愈疾病的个体化治疗提供了前所未有的机会。拟议的计划将产生临床药理学家，他们将受到良好的培训，以领导利用这些巨大机会的努力。

DESCRIPTION (provided by applicant): The University of North Carolina at Chapel Hill (UNC), in collaboration with Duke University and the Hamner Institute for Drug Safety Sciences, is well positioned for a T32 training program in clinical pharmacology. We have an outstanding research environment in clinical pharmacology with world-class programs in pharmacogenomics, drug discovery, drug development and drug safety, an outstanding track record of training clinician-scientists in clinical pharmacology, and an excellent applicant pool. The clinical pharmacology training program detailed in this application offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program will be derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology. Trainees, guided by individualized mentoring teams, will complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research, from ethics and pharmacogenomics to clinical trial design. Faculty mentors were chosen based on their productivity in clinical pharmacology research in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Pharmacogenomics; Drug-induced Organ Toxicity; Quantitative Pharmacology and Clinical Trial Design. A unique feature of this training program is the opportunity to focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our potential trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC, Duke University, and the Hamner-UNC Institute for Drug Safety Sciences, the intellectually-rich regional environment represented by Research Triangle Park with its concentration of biomedical sciences related to clinical pharmacology, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology. PUBLIC HEALTH RELEVANCE: There has been an explosion in understanding of the biology underlying disease and interindividual variation in response to pharmacotherapy. This has provided unprecedented opportunities in drug development and the individualization of therapy to treat and ultimately cure disease. The proposed program will produce clinical pharmacologists that will be well-trained to lead the effort to capitalize on these great opportunities.